ASCO 2025 | Phase I/II trial of DB-1311, a B7H3-tageting ADC, in pretreated CRPC
Andrew Ohyama Parsonson
• 2 Jun 2025
Andrew Ohyama Parsonson, FRACP, MBBS, Macquarie University, Sydney, Australia, discusses updated results from the Phase I/II trial (NCT05914116) of DB-1311, a novel B7H3 antibody-drug conjugate (ADC), in patients with heavily pretreated castrate-resistant prostate cancer (CRPC). The agent demonstrated promising antitumor activity and durable responses across both dose levels. The safety profile was manageable, with most adverse events being low grade. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
